目次

Table of Contents

List of Tables

List of Figures
Introduction
Global Markets Direct Report Coverage
Psoriatic Arthritis - Overview
Psoriatic Arthritis - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Psoriatic Arthritis - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Psoriatic Arthritis - Companies Involved in Therapeutics Development
Psoriatic Arthritis - Drug Profiles
Psoriatic Arthritis - Dormant Projects
Psoriatic Arthritis - Discontinued Products
Psoriatic Arthritis - Product Development Milestones
Featured News & Press Releases
Sep 26, 2022: MoonLake Immunotherapeutics to initiate global phase 2 study of the Nanobody sonelokimab in patients with active psoriatic arthritis
Sep 12, 2022: Cosentyx 300 mg Pen Approved in Japan: Novartis
Sep 10, 2022: AbbVie showcases new analyses and real-world data across multiple immune-mediated skin diseases at the European Academy of Dermatology and Venereology (EADV) 2022 Congress
Sep 10, 2022: New late-breaking results from phase 3 trials of SKYRIZI (risankizumab) evaluating long-term effect on skin and joint symptoms in patients with psoriatic arthritis at Week 100
Aug 24, 2022: Nimbus Therapeutics presents new data on oral allosteric TYK2 inhibitor at American Chemical Society Meeting
Aug 15, 2022: Ventyx Biosciences to report topline results from the phase 1 trial of its TYK 2 inhibitor VTX958 and second quarter 2022 financial results on August 15, 2022
Aug 15, 2022: Ventyx Biosciences announces positive topline phase 1 data for its selective allosteric TYK2 inhibitor VTX95
Aug 02, 2022: US FDA grants approval for Janssen's Stelara to treat psoriatic arthritis
Jul 21, 2022: Sandoz Supplemental Biologics License Application accepted by US FDA for biosimilar Hyrimoz (adalimumab-adaz) high concentration formulation (HCF)
Jun 04, 2022: New data show patients treated with first-in-Class TREMFYA (guselkumab) achieve durable efficacy across joint and axial Symptoms of active psoriatic arthritis through two years
Jun 03, 2022: ACELYRIN, Affibody and Inmagene Biopharmaceuticals announce data from global phase 2 trial of Izokibep in patients with psoriatic arthritis presented during 2022 European Alliance of Associations for Rheumatology Congress
May 23, 2022: UCB announces first detailed data from two phase 3 bimekizumab studies in psoriatic arthritis to be presented at EULAR 2022
May 18, 2022: New data show TREMFYA (guselkumab) binds to both inflammatory cells and interleukin (IL)-23, supporting a hypothesis for a differentiated mechanism from Risankizumab
May 16, 2022: Alvotech announces positive results from a pharmacokinetic similarity study for AVT04, a proposed biosimilar to Stelara
May 12, 2022: Amgen and Lance bBass partner to encourage people to do a 'double take' to recognize the early signs of psoriatic arthritis
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Psoriatic Arthritis, 2022
Number of Products under Development by Companies, 2022
Products under Development by Companies, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Mechanism of Action, 2022 (Contd..1)
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Psoriatic Arthritis - Dormant Projects, 2022
Psoriatic Arthritis - Dormant Projects, 2022 (Contd..1)
Psoriatic Arthritis - Dormant Projects, 2022 (Contd..2)
Psoriatic Arthritis - Dormant Projects, 2022 (Contd..3)
Psoriatic Arthritis - Discontinued Products, 2022

List of Figures
Number of Products under Development for Psoriatic Arthritis, 2022
Number of Products under Development by Companies, 2022
Number of Products by Top 10 Targets, 2022
Number of Products by Stage and Top 10 Targets, 2022
Number of Products by Top 10 Mechanism of Actions, 2022
Number of Products by Stage and Top 10 Mechanism of Actions, 2022
Number of Products by Routes of Administration, 2022
Number of Products by Stage and Routes of Administration, 2022
Number of Products by Molecule Types, 2022
Number of Products by Stage and Molecule Types, 2022